Argatroban Sawai

Argatroban Sawai Uses, Dosage, Side Effects, Food Interaction and all others data.

Argatroban Sawai is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban Sawai is a non-heparin anticoagulant shown to both normalize platelet count in patients with HIT and prevent the formation of thrombi. Parental anticoagulants must be stopped and a baseline activated partial thromboplastin time must be obtained prior to administering argatroban.

Argatroban Sawai is a synthetic direct thrombin inhibitor derived from L-arginine indicated as an anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia. Argatroban Sawai is a direct thrombin inhibitor that reversibly binds to the thrombin active site. Argatroban Sawai does not require the co-factor antithrombin III for antithrombotic activity. Argatroban Sawai exerts its anticoagulant effects by inhibiting thrombin-catalyzed or -induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; protein C; and platelet aggregation. Argatroban Sawai is highly selective for thrombin with an inhibitory constant (Ki) of 0.04 µM. At therapeutic concentrations, Argatroban Sawai has little or no effect on related serine proteases (trypsin, factor Xa, plasmin, and kallikrein).Argatroban Sawai is capable of inhibiting the action of both free and clot-associated thrombin.

Trade Name Argatroban Sawai
Availability Prescription only
Generic Argatroban
Argatroban Other Names Argatroban
Related Drugs warfarin, Coumadin, heparin, alteplase, Jantoven, streptokinase
Type
Formula C23H36N6O5S
Weight Average: 508.64
Monoisotopic: 508.246789457
Protein binding

54%

Groups Approved, Investigational
Therapeutic Class
Manufacturer
Available Country Japan
Last Updated: September 19, 2023 at 7:00 am
Argatroban Sawai
Argatroban Sawai

Uses

Argatroban Sawai is a synthetic direct thrombin inhibitor used for the prevention and treatment of thrombosis related to heparin use.

Argatroban Sawai is indicated for prevention and treatment of thrombosis caused by heparin-induced thrombocytopenia (HIT). It is also indicated for use in patients with, or at risk for, HIT who are undergoing percutaneous coronary intervention.

Argatroban Sawai is also used to associated treatment for these conditions: Thrombotic events

How Argatroban Sawai works

Argatroban Sawai exerts its anticoagulant effects by inhibiting thrombin-catalyzed or -induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; protein C; and platelet aggregation.

Toxicity

Excessive bleeding

Food Interaction

  • Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.
  • Exercise caution with grapefruit products. Grapefruit inhibits CYP3A4 metabolism, which may increase the serum concentration of argatroban; however, the evidence is conflicting.
  • Exercise caution with St. John's Wort.

Argatroban Sawai Disease Interaction

Major: active bleeding

Volume of Distribution

  • 174 mL/kg
  • 12.18 L [70-kg adult]

Elimination Route

Bioavailability is 100% (intravenous).

Half Life

39 and 51 minutes

Clearance

  • 5.1 L/kg/hr [infusion doses up to 40 mcg/kg/min]

Elimination Route

Argatroban Sawai is excreted primarily in the feces (65%), presumably through biliary secretion; 22% is eliminated via urine.

Innovators Monograph

You find simplified version here Argatroban Sawai

*** Taking medicines without doctor's advice can cause long-term problems.
Share